New hope for Tough-to-Treat stomach cancer
NCT ID NCT07332533
Summary
This study is testing a new combination of drugs (KN026 plus chemotherapy, with or without enlonstobart) against the current standard treatment for people with advanced HER2-positive stomach cancer that cannot be removed by surgery. It aims to see if the new combination works better at shrinking tumors and helping patients live longer without their cancer getting worse. The trial will enroll about 490 adults who haven't had prior treatment for their advanced cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.